Выбор редакции

More on ARIAD ([[ARIA]] -2.8%) Q2: net loss widens to $51.3M from $47.8M; revenue $318K vs. $66K and consensus of $1.93M. Commits to being ready for U.S. launch of leukemia drug ponatinib, which is under FDA review, by Oct. 31. After not receiving $25M milestone from Merck, ARIAD expects cash used in operations to be $162-167M in 2012. (PR)

More on ARIAD (ARIA -2.8%) Q2: net loss widens to $51.3M from $47.8M; revenue $318K vs. $66K and consensus of $1.93M. Commits to being ready for U.S. launch of leukemia drug ponatinib, which is under FDA review, by Oct. 31. After not receiving $25M milestone from Merck, ARIAD expects cash used in operations to be $162-167M in 2012. (PR) Post your comment!

НОВОСТИ ПО ТЕМЕ